UOC
DNTH icon

UBS O'Connor’s Dianthus Therapeutics DNTH Stock Holding History

UBS O'Connor’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-3,750
Closed -$810K – 291
2018
Q2 		$810K Buy
+3,750
New +$846K 0.02% 220

Other funds holding DNTH

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

UBS O'Connor's DNTH Position: Q3 2018 in Review

UBS O'Connor sold out of Dianthus Therapeutics (DNTH) in Q3 2018, closing a stake of 3,750 shares — an estimated $810K sold.

UBS O'Connor first reported a position in DNTH in Q2 2018 and held it in 1 quarter. The position peaked at $810K in Q2 2018. 51 funds tracked by Wall St. Rank hold DNTH as of Q3 2018.

  • UBS O'Connor reported no remaining Dianthus Therapeutics position as of Q3 2018 after selling out during the quarter.
  • UBS O'Connor sold 3,750 Dianthus Therapeutics shares in Q3 2018, an estimated $810K.
  • UBS O'Connor first reported a position in Dianthus Therapeutics in Q2 2018 and held it in 1 quarter.
  • UBS O'Connor's Dianthus Therapeutics position peaked at $810K in Q2 2018.
  • 51 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q3 2018.

Based on UBS O'Connor's 13F filing for Q3 2018, filed 14 Nov 2018.